These findings, clarify the relationship between NAT10 and the Wnt/β-catenin pathway in CRC for the first time and the results of the successful treatment of CRC cells in vitro and in vivo with remodelin implied that NAT10 has potential value in targeted CRC therapy. This evidence concerns the gene NAT10 and colorectal carcinoma.